Establishing non-inferiority in treatment trials in psychiatry — guidelines from an Expert Consensus Meeting

Comparing the efficacy of different treatments in psychiatry is difficult for many reasons, even when they are investigated in `head-to-head' studies. A consensus meeting was, therefore, held to produce best practice guidelines for such studies. This article presents the conclusions of this consensus and illustrates it using published data in the field of antidepressant treatment of generalized anxiety disorder.

[1]  D. Nutt,et al.  Development and validation of the Generalized Anxiety Disorder Inventory (GADI) , 2006, Journal of psychopharmacology.

[2]  P. Gøtzsche.  [Noninferiority and equivalence randomized trials: lessons and reservations--secondary publication]. , 2006, Ugeskrift for læger.

[3]  D. Baldwin,et al.  Escitalopram in the treatment of generalized anxiety disorder , 2005, Expert review of neurotherapeutics.

[4]  A. Reynolds,et al.  A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. , 2003 .

[5]  D. Sheehan,et al.  Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.

[6]  Yi Tsong,et al.  Some fundamental issues with non‐inferiority testing in active controlled trials , 2002, Statistics in medicine.

[7]  C. Allgulander,et al.  Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder , 2001, British Journal of Psychiatry.

[8]  M. Pollack,et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.

[9]  A. Gelenberg,et al.  Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. , 2000, JAMA.

[10]  D. Sheehan,et al.  Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. , 2000, The American journal of psychiatry.

[11]  J. Davidson,et al.  Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. , 1999, The Journal of clinical psychiatry.